13411 - REACT Postdoctoral Research Associate (Genetic Switches for Cardiovascular Diseases)
| Posting date: | 21 November 2025 |
|---|---|
| Salary: | £41,064 to £48,822 per year |
| Hours: | Full time |
| Closing date: | 19 December 2025 |
| Location: | Edinburgh, Scotland |
| Remote working: | On-site only |
| Company: | University of Edinburgh |
| Job type: | Temporary |
| Job reference: | 13411 |
Summary
UE07 £41,064 - £48,822
College of Science and Engineering / School of Biological Sciences / Institute of Quantitative Biology, Biochemistry and Biotechnology
Full-Time 35hrs per week
Fixed Term: 24 months
We are looking to employ a postdoctoral researcher on a 24 month contract to join the research group of Professor Susan Rosser, chair of synthetic biology at the University of Edinburgh Centre for Engineering Biology to work on developing gene switches for use in cardio vascular gene therapy.
The Opportunity:
The selected researcher will join an internationally recognised, friendly, diverse, inclusive and enthusiastic team. It is in collaboration with Prof. Brian Bigger, chair of advanced therapeutic and is an excellent opportunity to work at the crossroads of Engineering Biology (Rosser lab) and translational gene therapy (Bigger lab), and generating pioneering research with expected tangible impact for patients suffering from cardiac diseases.
You will become part of the REACT consortium whose mission is to
regenerate injured hearts and reverse established damage with genetic medicines. It is a 14-year funded £50M MRC/BHF centre of research of excellence led by King’s College London and co-directed by the University of Edinburgh and Oxford.
As part of this role, you will use an engineering biology-based approach to develop, test and optimise drug-induced controllable genetic switches for use in clinical AAV vectors. We aim to create a control system that is specific, tuneable and with minimal side effects. This will let us iteratively refine these switches to reliably turn therapeutic genes on and off for cardiovascular treatment
Your work will also closely align to the Engineering Biology for Advanced Therapeutics Hub. The hub, Directed by Prof Rosser, is a £14M 5-year UKRI sponsored research program across 4 institutions (Edinburgh, Oxford, Imperial, CRUK SI) pioneering engineering biology for advanced therapeutics. It is developing novel genetic tools to render gene therapies safe and effective, with initial focus on oncology, cardiovascular diseases and rare diseases.
The post holder will have many opportunities for multidisciplinary collaborative working with academic colleagues from the different institutional partners and industry partners. This includes training and professional development opportunities arising from being embedded and working with communities of translational scientists.
This post offers an excellent opportunity for academic career advancement in a worlds renowned centre of excellence for synthetic/engineering biology. The University of Edinburgh hosts a large diverse, dynamic and multidisciplinary engineering biology community of more than 50 research groups. The University of Edinburgh’s synthetic biology facilities are second-to-none, and include a the Edinburgh Genome Foundry (https://biology.ed.ac.uk/research/facilities/edinburgh-genome-foundry) and Edinomics (https://biology.ed.ac.uk/research/facilities/edinomics).
Applicants must have a PhD in synthetic/engineering biology, molecular biology, RNA biology for appointment at Research Associate level. Applicants close to completion of their PhDs will also be considered where experience is directly relevant. Please see the job description and person specification document associated with this advert for the full list of criteria.
This post is advertised as full-time (35 hours per week), however, we are open to considering part-time or flexible working patterns.
Your skills and attributes for success:
PhD (or completion within 3 months) in engineering biology or related subject with synthetic/engineering biology experience
Experience in engineering biology, RNA biology and molecular biology.
Experience of mammalian Cell Engineering
Excellent written and verbal communication skills with ability to build rapport with colleagues and collaborators.
College of Science and Engineering / School of Biological Sciences / Institute of Quantitative Biology, Biochemistry and Biotechnology
Full-Time 35hrs per week
Fixed Term: 24 months
We are looking to employ a postdoctoral researcher on a 24 month contract to join the research group of Professor Susan Rosser, chair of synthetic biology at the University of Edinburgh Centre for Engineering Biology to work on developing gene switches for use in cardio vascular gene therapy.
The Opportunity:
The selected researcher will join an internationally recognised, friendly, diverse, inclusive and enthusiastic team. It is in collaboration with Prof. Brian Bigger, chair of advanced therapeutic and is an excellent opportunity to work at the crossroads of Engineering Biology (Rosser lab) and translational gene therapy (Bigger lab), and generating pioneering research with expected tangible impact for patients suffering from cardiac diseases.
You will become part of the REACT consortium whose mission is to
regenerate injured hearts and reverse established damage with genetic medicines. It is a 14-year funded £50M MRC/BHF centre of research of excellence led by King’s College London and co-directed by the University of Edinburgh and Oxford.
As part of this role, you will use an engineering biology-based approach to develop, test and optimise drug-induced controllable genetic switches for use in clinical AAV vectors. We aim to create a control system that is specific, tuneable and with minimal side effects. This will let us iteratively refine these switches to reliably turn therapeutic genes on and off for cardiovascular treatment
Your work will also closely align to the Engineering Biology for Advanced Therapeutics Hub. The hub, Directed by Prof Rosser, is a £14M 5-year UKRI sponsored research program across 4 institutions (Edinburgh, Oxford, Imperial, CRUK SI) pioneering engineering biology for advanced therapeutics. It is developing novel genetic tools to render gene therapies safe and effective, with initial focus on oncology, cardiovascular diseases and rare diseases.
The post holder will have many opportunities for multidisciplinary collaborative working with academic colleagues from the different institutional partners and industry partners. This includes training and professional development opportunities arising from being embedded and working with communities of translational scientists.
This post offers an excellent opportunity for academic career advancement in a worlds renowned centre of excellence for synthetic/engineering biology. The University of Edinburgh hosts a large diverse, dynamic and multidisciplinary engineering biology community of more than 50 research groups. The University of Edinburgh’s synthetic biology facilities are second-to-none, and include a the Edinburgh Genome Foundry (https://biology.ed.ac.uk/research/facilities/edinburgh-genome-foundry) and Edinomics (https://biology.ed.ac.uk/research/facilities/edinomics).
Applicants must have a PhD in synthetic/engineering biology, molecular biology, RNA biology for appointment at Research Associate level. Applicants close to completion of their PhDs will also be considered where experience is directly relevant. Please see the job description and person specification document associated with this advert for the full list of criteria.
This post is advertised as full-time (35 hours per week), however, we are open to considering part-time or flexible working patterns.
Your skills and attributes for success:
PhD (or completion within 3 months) in engineering biology or related subject with synthetic/engineering biology experience
Experience in engineering biology, RNA biology and molecular biology.
Experience of mammalian Cell Engineering
Excellent written and verbal communication skills with ability to build rapport with colleagues and collaborators.